DK3067358T3 - Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse - Google Patents

Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse Download PDF

Info

Publication number
DK3067358T3
DK3067358T3 DK15201519T DK15201519T DK3067358T3 DK 3067358 T3 DK3067358 T3 DK 3067358T3 DK 15201519 T DK15201519 T DK 15201519T DK 15201519 T DK15201519 T DK 15201519T DK 3067358 T3 DK3067358 T3 DK 3067358T3
Authority
DK
Denmark
Prior art keywords
carbamoylpyridon
polycyclic
compounds
pharmaceutical use
pharmaceutical
Prior art date
Application number
DK15201519T
Other languages
English (en)
Inventor
Haolun Jin
Scott E Lazerwith
Teresa Alejandra Trejo Martin
Elizabeth M Bacon
Jeromy J Cottell
Zhenhong R Cai
Hyung-Jung Pyun
Philip Anthony Morganelli
Mingzhe Ji
James G Taylor
Xiaowu Chen
Michael R Mish
Manoj C Desai
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49917297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3067358(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of DK3067358T3 publication Critical patent/DK3067358T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15201519T 2012-12-21 2013-12-19 Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse DK3067358T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261745375P 2012-12-21 2012-12-21
US201361788397P 2013-03-15 2013-03-15
US201361845803P 2013-07-12 2013-07-12
EP13815937.1A EP2822954B1 (en) 2012-12-21 2013-12-19 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use

Publications (1)

Publication Number Publication Date
DK3067358T3 true DK3067358T3 (da) 2019-11-04

Family

ID=49917297

Family Applications (3)

Application Number Title Priority Date Filing Date
DK15201519T DK3067358T3 (da) 2012-12-21 2013-12-19 Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse
DK19185121.1T DK3608325T3 (da) 2012-12-21 2013-12-19 Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse
DK13815937.1T DK2822954T3 (da) 2012-12-21 2013-12-19 Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK19185121.1T DK3608325T3 (da) 2012-12-21 2013-12-19 Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse
DK13815937.1T DK2822954T3 (da) 2012-12-21 2013-12-19 Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse

Country Status (42)

Country Link
US (6) US9216996B2 (da)
EP (4) EP3608325B1 (da)
JP (6) JP6028105B2 (da)
KR (8) KR20230061576A (da)
CN (4) CN111303152B (da)
AP (1) AP2015008510A0 (da)
AR (1) AR094197A1 (da)
AU (6) AU2013361401C1 (da)
BR (2) BR112015014714B1 (da)
CA (3) CA3131094A1 (da)
CL (3) CL2015001756A1 (da)
CR (2) CR20170279A (da)
CY (3) CY1117570T1 (da)
DK (3) DK3067358T3 (da)
EA (2) EA037633B1 (da)
ES (3) ES2926068T3 (da)
HK (3) HK1205124A1 (da)
HR (3) HRP20220899T1 (da)
HU (4) HUE046559T2 (da)
IL (4) IL239316A (da)
LT (3) LT3067358T (da)
LU (1) LUC00083I2 (da)
MD (3) MD4736C1 (da)
ME (1) ME02400B (da)
MX (4) MX344879B (da)
MY (2) MY164352A (da)
NL (1) NL300947I2 (da)
NO (1) NO2018026I2 (da)
NZ (2) NZ718708A (da)
PE (2) PE20151499A1 (da)
PH (3) PH12019501848A1 (da)
PL (3) PL3608325T3 (da)
PT (3) PT3067358T (da)
RS (1) RS54873B1 (da)
SG (1) SG11201504857SA (da)
SI (3) SI2822954T1 (da)
SM (1) SMT201600157B (da)
TW (5) TWI830624B (da)
UA (2) UA114351C2 (da)
UY (1) UY35213A (da)
WO (1) WO2014100323A1 (da)
ZA (2) ZA201507997B (da)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6205354B2 (ja) 2011-07-06 2017-09-27 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のための化合物
KR20200127273A (ko) 2012-04-26 2020-11-10 브리스톨-마이어스 스큅 컴퍼니 혈소판 응집을 치료하기 위한 프로테아제 활성화 수용체 4 (par4) 억제제로서의 이미다조티아디아졸 및 이미다조피라진 유도체
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
ES2926068T3 (es) 2012-12-21 2022-10-21 Gilead Sciences Inc Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ME03780B (me) 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
PT3252058T (pt) * 2013-07-12 2021-03-09 Gilead Sciences Inc Compostos policíclicos-carbamoílpiridona e seu uso para o tratamento de infecções por hiv
NO2865735T3 (da) * 2013-07-12 2018-07-21
PE20160532A1 (es) 2013-08-23 2016-05-21 Incyte Corp Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim
WO2015177537A1 (en) * 2014-05-20 2015-11-26 Cipla Limited Process for preparing polycyclic carbamoyl pyridone derivatives and intermediates thereof
PL3157915T3 (pl) 2014-06-17 2019-07-31 Pfizer Inc. Podstawione związki dihydroizochinolinonowe
TWI677489B (zh) * 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (da) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
JPWO2016027879A1 (ja) * 2014-08-22 2017-06-01 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
US20160067255A1 (en) 2014-09-04 2016-03-10 Gilead Sciences, Inc. Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
WO2016090545A1 (en) 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrate inhibitors
TWI738321B (zh) * 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
US9701677B2 (en) 2014-12-24 2017-07-11 Gilead Sciences, Inc. Fused pyrimidine compounds
AU2015371257B2 (en) 2014-12-24 2018-09-06 Gilead Sciences, Inc. Isoquinoline compounds for the treatment of HIV
RS62434B1 (sr) 2014-12-26 2021-11-30 Univ Emory Antivirusni n4-hidroksicitidin derivati
CA2978188C (en) 2015-03-04 2020-05-12 Gilead Sciences, Inc. Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
ES2837383T3 (es) * 2015-04-02 2021-06-30 Gilead Sciences Inc Compuestos de carbamoilpiridonas policíclicos y su utilización farmacéutica
LT3428170T (lt) * 2015-04-28 2021-02-10 Shionogi & Co., Ltd Policiklinis piridono darinys nuo gripo ir jo provaistas
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
MA42684A (fr) 2015-08-26 2018-07-04 Gilead Sciences Inc Modulateurs deutérés du récepteur toll
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
AU2016330895A1 (en) 2015-09-30 2018-05-10 Gilead Sciences, Inc. Compounds and combinations for the treatment of HIV
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
SG11201802983TA (en) * 2015-11-09 2018-05-30 Gilead Sciences Inc Therapeutic compositions for treatment of human immunodeficiency virus
UA125819C2 (uk) 2015-12-15 2022-06-15 Гіліад Сайєнсіз, Інк. ВИДІЛЕНЕ МОНОКЛОНАЛЬНЕ АНТИТІЛО, ЩО ЗВ'ЯЗУЄТЬСЯ З gp120 ВІРУСУ ІМУНОДЕФІЦИТУ ЛЮДИНИ
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2018005328A1 (en) * 2016-06-27 2018-01-04 Concert Pharmaceuticals, Inc. Deuterated bictegravir
MX369307B (es) 2016-08-19 2019-11-05 Gilead Sciences Inc Compuestos terapeuticos utiles para tratamiento profilactico o terapeutico de infeccion por virus de inmunodeficiencia humana.
WO2018042331A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018042332A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018045144A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
WO2018051250A1 (en) 2016-09-14 2018-03-22 Viiv Healthcare Company Combination comprising tenofovir alafenamide, bictegravir and 3tc
EP3518935A1 (en) 2016-09-27 2019-08-07 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
EP3519409B1 (en) 2016-09-28 2024-09-18 Gilead Sciences, Inc. Benzothiazol-6-yl acetic acid derivatives and their use for treating hiv infection
ES2881949T3 (es) 2016-10-27 2021-11-30 Gilead Sciences Inc Forma cristalina de base libre de darunavir
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
CN108250215B (zh) * 2016-12-28 2022-04-19 华创合成制药股份有限公司 一种新型抗hiv药物及其制备方法和用途
TWI784370B (zh) 2017-01-31 2022-11-21 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
CN106860464A (zh) * 2017-02-16 2017-06-20 江苏艾迪药业有限公司 用于联合抗病毒治疗的药物组合物及应用
CN106860414B (zh) * 2017-02-16 2019-12-24 江苏艾迪药业股份有限公司 一种用于抗hiv的复方制剂及其制备方法与应用
WO2018229798A1 (en) 2017-06-13 2018-12-20 Cipla Limited Process for the preparation of bictegravir and intermediate thereof
TWI728250B (zh) 2017-06-21 2021-05-21 美商基利科學股份有限公司 靶向hiv gp120及cd3之多特異性抗體
PL3661937T3 (pl) 2017-08-01 2021-12-20 Gilead Sciences, Inc. Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych
US20200171039A1 (en) * 2017-08-09 2020-06-04 Viiv Healthcare Company Combinations and uses and treatments
WO2019030625A1 (en) 2017-08-09 2019-02-14 Viiv Healthcare Company COMBINATIONS, USES AND CORRESPONDING TREATMENTS
TW202024061A (zh) 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
SG11202002789XA (en) 2017-10-06 2020-04-29 Shionogi & Co Stereoselective process for preparing substituted polycyclic pyridone derivatives
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
EP3700573A1 (en) 2017-10-24 2020-09-02 Gilead Sciences, Inc. Methods of treating patients co-infected with a virus and tuberculosis
CN111372592A (zh) 2017-12-07 2020-07-03 埃默里大学 N4-羟基胞苷及衍生物和与其相关的抗病毒用途
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
EP3740209A1 (en) * 2018-01-19 2020-11-25 Gilead Sciences, Inc. Metabolites of bictegravir
CA3088596A1 (en) 2018-02-09 2019-08-15 Sandoz Ag Crystalline form of bictegravir sodium
AU2019221568B2 (en) 2018-02-15 2021-04-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating HIV infection
WO2019159199A1 (en) 2018-02-16 2019-08-22 Cipla Limited Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof
EP3752496B1 (en) 2018-02-16 2023-07-05 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
CN109020911B (zh) * 2018-04-16 2022-06-28 常州制药厂有限公司 用于制备bictegravir的中间体及其制备方法
CA3098274A1 (en) 2018-04-26 2019-10-31 Mylan Laboratories Limited Polymorphic forms of bictegravir and its sodium salt
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
CN110526930B (zh) * 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
US11453669B2 (en) 2018-05-31 2022-09-27 Shionogi & Co., Ltd. Polycyclic pyridone derivative
LT3805220T (lt) 2018-05-31 2024-08-26 Shionogi & Co., Ltd Policikliniai karbamoilpiridono dariniai, skirti živ gydymui
WO2020004443A1 (ja) 2018-06-27 2020-01-02 国立大学法人北海道大学 多環性カルバモイルピリドン誘導体を含有するアレナウイルス増殖阻害剤
US11623933B2 (en) 2018-06-28 2023-04-11 Honour Lab Limited Process for the preparation of sodium (2R,5S,13AR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl) carbamoyl)-2,3,4,5,7,9,13,13A-octahydro-2,5-Methanopyrido[1 ′,2′:4,5]pyrazino[2,1 -b] [1,3] oxazepin-8-olate and its polymorphic form
SG11202012043RA (en) 2018-07-03 2021-01-28 Gilead Sciences Inc Antibodies that target hiv gp120 and methods of use
EP3820875B1 (en) 2018-07-12 2024-01-17 Laurus Labs Limited A process for purification of protected polycyclic carbamoylpyridone derivatives
KR20210033492A (ko) 2018-07-16 2021-03-26 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
TWI829205B (zh) 2018-07-30 2024-01-11 美商基利科學股份有限公司 抗hiv化合物
EP3852761A1 (en) 2018-09-19 2021-07-28 Gilead Sciences, Inc. Integrase inhibitors for the prevention of hiv
EP3860717A1 (en) 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
JP7437051B2 (ja) 2018-10-22 2024-02-22 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ 抗ウイルスプロドラッグおよびそのナノ製剤
EP3873903B1 (en) 2018-10-31 2024-01-24 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
EP3653629A1 (en) 2018-11-16 2020-05-20 Sandoz AG Acid addition salts of an integrase strand transfer inhibitor
US20220144851A1 (en) 2019-02-07 2022-05-12 Cipla Limited Novel polymorphs of integrase inhibitor
WO2020176510A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
WO2020176505A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
KR20210137518A (ko) 2019-03-07 2021-11-17 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
CN113543851A (zh) 2019-03-07 2021-10-22 捷克共和国有机化学与生物化学研究所 2’3’-环二核苷酸及其前药
EP4122537A1 (en) * 2019-03-22 2023-01-25 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
WO2020214647A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of an hiv protease inhibitor
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202231277A (zh) 2019-05-21 2022-08-16 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
CN110229174A (zh) * 2019-05-22 2019-09-13 博诺康源(北京)药业科技有限公司 Bictegravir原料药基因毒性杂质的合成方法
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
CN110263404B (zh) * 2019-06-12 2023-03-21 江苏大学 一种基于dpm模型的一体化预制泵站沉积特性的计算方法
WO2020255038A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
WO2020255004A1 (en) * 2019-06-18 2020-12-24 Laurus Labs Limited Process and polymorphic forms of bictegravir and its pharmaceutically acceptable salts or co-crystals thereof
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
CA3142513A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
KR20220047277A (ko) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
CN110698473B (zh) * 2019-10-08 2020-12-18 浙江大学 哌嗪酮并羟基吡啶酮-5-羧基类化合物及制备和应用
CN114727999A (zh) 2019-11-26 2022-07-08 吉利德科学公司 用于预防hiv的衣壳抑制剂
JPWO2021107065A1 (da) * 2019-11-28 2021-06-03
US20230059640A1 (en) 2019-11-28 2023-02-23 Shionogi & Co., Ltd. Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent
CN117736207A (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
AU2021225809B2 (en) 2020-02-24 2023-08-24 Gilead Sciences, Inc. Tetracyclic compounds for treating HIV infection
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
EP4153181A1 (en) 2020-05-21 2023-03-29 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
CN113698420A (zh) * 2020-05-22 2021-11-26 上海迪赛诺生物医药有限公司 比克替拉韦钠的新晶型及其制备方法
CN115996925A (zh) 2020-06-25 2023-04-21 吉利德科学公司 用于治疗hiv的衣壳抑制剂
PE20230779A1 (es) 2020-08-07 2023-05-09 Gilead Sciences Inc Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico
KR20230079137A (ko) 2020-09-30 2023-06-05 길리애드 사이언시즈, 인코포레이티드 가교된 트리사이클릭 카르바모일피리돈 화합물 및 이의 용도
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN114426540B (zh) * 2020-10-29 2024-04-26 上海拓界生物医药科技有限公司 吡啶并[1,2-a]吡嗪-1,8-二酮类前药衍生物、其制备方法及其应用
TW202227445A (zh) * 2020-10-30 2022-07-16 大陸商上海拓界生物醫藥科技有限公司 抑制基因缺陷的ｈｉｖ病毒的用途
KR20230107288A (ko) 2020-11-11 2023-07-14 길리애드 사이언시즈, 인코포레이티드 gp120 CD4 결합 부위-지향 항체를 이용한 요법에 감수성인 HIV 환자를 식별하는 방법
CR20230315A (es) 2021-01-19 2023-09-01 Gilead Sciences Inc Compuestos de piridotriazina sustituidos y usos de estos
WO2022157561A1 (en) * 2021-01-22 2022-07-28 Laurus Labs Limited Processes for purification of bictegravir intermediates
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117751118A (zh) * 2021-07-30 2024-03-22 吉斯凯(苏州)制药有限公司 大环吡啶酮类化合物及其应用
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
KR20240117588A (ko) 2021-12-03 2024-08-01 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
EP4440702A1 (en) 2021-12-03 2024-10-09 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
CN114605437A (zh) * 2022-04-01 2022-06-10 遵义医科大学 连续一锅法制备三个替拉韦药物的合成工艺
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2023248240A1 (en) 2022-06-21 2023-12-28 Mylan Laboratories Limited Polymorphic forms of bictegravir sodium
WO2024006982A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024044477A1 (en) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024061257A1 (zh) * 2022-09-20 2024-03-28 吉斯凯(苏州)制药有限公司 多环氮杂环酮类化合物及其应用
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788516A (fr) 1971-09-10 1973-03-07 Lonza Ag Procede de fabrication d'esters alcoxyacetylacetiques
GB1528382A (en) 1974-12-26 1978-10-11 Teijin Ltd Cyclopentene diols and acyl esters thereof and processes for their preparation
DE2658401A1 (de) 1976-12-23 1978-07-06 Merck Patent Gmbh Cyclopentan-1-amine, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
US4575694A (en) 1984-03-05 1986-03-11 Allied Corporation Coaxial connector
DE3900735A1 (de) 1989-01-12 1990-07-26 Hoechst Ag Neue mehrfunktionelle (alpha)-diazo-(beta)-ketoester, verfahren zu ihrer herstellung und deren verwendung
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
DE4014649A1 (de) 1990-05-08 1991-11-14 Hoechst Ag Neue mehrfunktionelle verbindungen mit (alpha)-diazo-ss-ketoester- und sulfonsaeureester-einheiten, verfahren zu ihrer herstellung und deren verwendung
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
SE9702772D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
WO1999025345A1 (en) 1997-11-14 1999-05-27 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
CA2346108A1 (en) 1998-11-09 2000-05-18 James Black Foundation Limited Gastrin and cholecystokinin receptor ligands
GB2345058A (en) 1998-12-01 2000-06-28 Cerebrus Pharm Ltd Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system
CZ20012160A3 (cs) 1998-12-25 2001-10-17 Shionogi & Co., Ltd. Heteroaromatické deriváty s inhibiční aktivitou proti HIV integráze
EP1297834A4 (en) 2000-06-14 2007-05-09 Shionogi & Co ENZYME INHIBITOR HAVING TWO DIVALENT METAL IONS AS ACTIVE CENTERS
EP1326611B1 (en) * 2000-10-12 2007-06-13 Merck & Co., Inc. Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
DK3042894T1 (da) 2001-08-10 2016-11-07 Shionogi & Co Antiviralt middel
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
CZ2004442A3 (cs) 2001-10-03 2005-03-16 Ucb, S.A. Pyrrolidinonové deriváty
CN102219750B (zh) 2001-10-26 2013-05-29 P.安杰莱蒂分子生物学研究所 关于hiv整合酶的n-取代的羟基嘧啶酮甲酰胺抑制剂
US7109186B2 (en) 2002-07-09 2006-09-19 Bristol-Myers Squibb Company HIV integrase inhibitors
CA2498111A1 (en) 2002-09-11 2004-03-25 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
CA2470365C (en) 2002-11-20 2011-05-17 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
ATE398455T1 (de) 2003-01-14 2008-07-15 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
AU2005211349A1 (en) 2004-01-30 2005-08-18 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. N-benzyl-3,4-dihyroxypyridine-2-carboxamide and N-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as HIV integrase inhibitors
EP1720856B1 (en) 2004-02-11 2013-08-14 GlaxoSmithKline LLC Hiv integrase inhibitors
US7619086B2 (en) 2004-03-09 2009-11-17 Merck & Co., Inc. HIV integrase inhibitors
WO2006028523A2 (en) 2004-04-29 2006-03-16 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO USDC Technology Transfer Office Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors
WO2005110399A2 (en) 2004-04-29 2005-11-24 The Regents Of The University Of California Zinc-binding groups for metalloprotein inhibitors
US7538112B2 (en) 2004-05-07 2009-05-26 Merck & Co., Inc. HIV integrase inhibitors
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
WO2005110411A1 (en) * 2004-05-17 2005-11-24 Tibotec Pharmaceuticals Ltd. Combinations of substituted 1-phenyl-1,5-dihydro-pyrido- [3,2-b] indol-2-ones and other hiv inhibitors
US7531554B2 (en) 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
JP4629104B2 (ja) 2004-05-21 2011-02-09 日本たばこ産業株式会社 ４−オキソキノリン誘導体および抗ｈｉｖ剤を含む併用剤
EP1790638B1 (en) 2004-09-15 2013-04-03 Shionogi Co., Ltd. Carbamoylpyridone derivative having hiv integrase inhibitory activity
JP2006118669A (ja) 2004-10-25 2006-05-11 Sanoh Industrial Co Ltd 樹脂チューブ
CA2634499A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
ATE516026T1 (de) 2005-02-21 2011-07-15 Shionogi & Co Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung
ES2567197T3 (es) 2005-04-28 2016-04-20 Viiv Healthcare Company Derivado de carbamoilpiridona policíclico que tiene actividad inhibidora de la integrasa del VIH
AR057023A1 (es) 2005-05-16 2007-11-14 Gilead Sciences Inc Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
EP1906971A2 (en) 2005-07-27 2008-04-09 Gilead Sciences, Inc. Antiviral compounds
AU2006307101A1 (en) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
EP2308490A1 (en) 2005-12-30 2011-04-13 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
US20090018162A1 (en) 2006-02-01 2009-01-15 Yuji Matsuzaki Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
CN101437801B (zh) 2006-03-06 2013-02-06 日本烟草产业株式会社 制备4-氧代喹啉化合物的方法
ES2531190T3 (es) 2006-03-06 2015-03-11 Japan Tobacco Inc Método para producir un compuesto de 4-oxoquinolina
US7893055B2 (en) 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
AU2007275805A1 (en) 2006-07-19 2008-01-24 University Of Georgia Research Foundation, Inc. Pyridinone diketo acids: Inhibitors of HIV replication in combination therapy
TWI411602B (zh) 2006-09-12 2013-10-11 Gilead Sciences Inc 製造整合酶抑制劑的方法及彼所用的中間物
WO2008048538A1 (en) 2006-10-18 2008-04-24 Merck & Co., Inc. Hiv integrase inhibitors
LT2487166T (lt) 2007-02-23 2016-11-10 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
US20080280945A1 (en) 2007-05-09 2008-11-13 Sachin Lohani Crystalline forms of an HIV integrase inhibitor
WO2009006203A1 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
JP5547066B2 (ja) 2007-06-29 2014-07-09 ギリアード サイエンシーズ， インコーポレイテッド 治療用組成物およびその使用
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
WO2009018320A1 (en) 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Pyrone analog compositions and methods
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
EP2220046B1 (en) 2007-11-16 2014-06-18 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0803019D0 (en) 2008-02-19 2008-03-26 Btg Int Ltd Fluorinated compounds
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
US20100272811A1 (en) 2008-07-23 2010-10-28 Alkermes,Inc. Complex of trospium and pharmaceutical compositions thereof
WO2010011818A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011815A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011819A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
PT2320908E (pt) 2008-07-25 2014-03-06 Shionogi & Co Pró-fármacos de dolutegravir
ES2449752T3 (es) 2008-07-25 2014-03-21 Viiv Healthcare Company Proceso para la preparación de un derivado de pirido[1,2-a]pirrolo[1',2':3,4]imidazo[1,2-d]piracin-8-carboxamida
KR101695807B1 (ko) 2008-07-25 2017-01-13 비이브 헬쓰케어 컴퍼니 화합물
MX2011006241A (es) * 2008-12-11 2011-06-28 Shionogi & Co Sintesis de inhibidores de integrasa de vih de carbamoil-piridona e intermediarios.
ES2964383T3 (es) 2008-12-11 2024-04-05 Viiv Healthcare Co Procesos e intermedios para inhibidores de la integrasa del VIH de carbamoilpiridona
AU2009333653B2 (en) 2008-12-17 2015-09-10 Merck Patent Gmbh C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
SG10201706215UA (en) 2009-02-06 2017-08-30 Gilead Sciences Inc Tablets for combination therapy
TWI518084B (zh) * 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
JP5697163B2 (ja) 2009-03-26 2015-04-08 塩野義製薬株式会社 置換された３−ヒドロキシ−４−ピリドン誘導体
WO2010147068A1 (ja) 2009-06-15 2010-12-23 塩野義製薬株式会社 置換された多環性カルバモイルピリドン誘導体
WO2011028044A2 (ko) 2009-09-02 2011-03-10 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
KR20170078868A (ko) 2010-01-27 2017-07-07 비이브 헬쓰케어 컴퍼니 항바이러스 치료
JP5765965B2 (ja) 2010-02-26 2015-08-19 日本たばこ産業株式会社 １，３，４，８−テトラヒドロ−２Ｈ−ピリド［１，２−ａ］ピラジン誘導体及びそのＨＩＶインテグラーゼ阻害剤としての利用
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
BR112013000043A2 (pt) 2010-07-02 2019-09-24 Gilead Sciences Inc derivados de ácido naft-2-ilacético para tratar aids
NZ604716A (en) 2010-07-02 2014-12-24 Gilead Sciences Inc 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
EP2595986A2 (en) 2010-07-14 2013-05-29 Addex Pharma SA Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
CN103154004B (zh) 2010-08-05 2016-07-06 盐野义制药株式会社 具有hiv整合酶抑制活性的化合物的制造方法
MX2013003139A (es) 2010-09-24 2013-06-18 Shionogi & Co Profarmaco de derivado de carbamoilpiridona policiclica substituida.
ME01980B (me) 2010-11-19 2015-05-20 Gilead Sciences Inc Terapeutske kompozicije koje sadrže rilpivirin hcl i tenofovir dizoproksil fumarat
WO2012106534A2 (en) 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
SG194512A1 (en) 2011-04-21 2013-12-30 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
WO2012151567A1 (en) 2011-05-05 2012-11-08 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for preventing and treating influenza
US9121496B2 (en) 2011-06-29 2015-09-01 Arvinmeritor Technology, Llc Drive axle system and a method of control
JP6205354B2 (ja) 2011-07-06 2017-09-27 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のための化合物
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
ES2651212T3 (es) 2011-07-07 2018-01-25 Janssen Sciences Ireland Uc Formulaciones combinadas de darunavir
ES2613180T3 (es) 2011-09-14 2017-05-23 Mapi Pharma Limited Forma amorfa de la sal sódica dolutegravir
US9200009B2 (en) 2011-10-12 2015-12-01 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
JP6147761B2 (ja) 2011-12-12 2017-06-14 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ アミノ置換イミダゾピリダジン
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
WO2014008636A1 (en) 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Macrocyclic compounds as hiv integrase inhibitors
EP2875024A4 (en) 2012-07-20 2015-12-23 Merck Sharp & Dohme HIV TREATMENT WITH AMIDOSUBSTITUTED PYRIMIDINONE DERIVATIVES
US20150218164A1 (en) 2012-07-25 2015-08-06 Merck Sharp & Dohme Corp. Substituted naphthyridinedione derivatives as hiv integrase inhibitors
ES2608860T3 (es) 2012-08-03 2017-04-17 Gilead Sciences, Inc. Proceso e intermedios para preparar inhibidores de la integrasa
SG11201503397YA (en) 2012-11-08 2015-05-28 Bristol Myers Squibb Co Heteroaryl substituted pyridyl compounds useful as kinase modulators
SG10201704467SA (en) 2012-12-14 2017-06-29 Glaxosmithkline Llc Pharmaceutical compositions
US9714243B2 (en) 2012-12-17 2017-07-25 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as HIV integrase inhibitors
US20140221355A1 (en) 2012-12-21 2014-08-07 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
ES2926068T3 (es) 2012-12-21 2022-10-21 Gilead Sciences Inc Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
WO2014100077A1 (en) 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. Gastro-retentive formulations
US20140221378A1 (en) 2012-12-27 2014-08-07 Japan Tobacco Inc. SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR
EP2986291B1 (en) 2013-04-16 2020-05-27 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
WO2014200880A1 (en) 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
PT3252058T (pt) 2013-07-12 2021-03-09 Gilead Sciences Inc Compostos policíclicos-carbamoílpiridona e seu uso para o tratamento de infecções por hiv
NO2865735T3 (da) 2013-07-12 2018-07-21
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
AP2016009157A0 (en) 2013-09-27 2016-04-30 Merck Sharp & Dohme Substituted quinolizine derivatives useful as hiv integrase inhibitors
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
US9856271B2 (en) 2014-01-21 2018-01-02 Laurus Labs Limited Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
WO2015138933A1 (en) 2014-03-13 2015-09-17 Assia Chemical Industries Ltd. Solid state forms of dolutegravir sodium
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (da) 2014-06-20 2018-06-23
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TWI806081B (zh) * 2014-07-11 2023-06-21 美商基利科學股份有限公司 用於治療HIV之toll樣受體調節劑
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
ES2837383T3 (es) 2015-04-02 2021-06-30 Gilead Sciences Inc Compuestos de carbamoilpiridonas policíclicos y su utilización farmacéutica
CA2921336A1 (en) 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
WO2017004244A1 (en) 2015-06-30 2017-01-05 Gilead Sciences, Inc. Pharmaceutical formulations comprising tenofovir and emtricitabine
SG11201802983TA (en) 2015-11-09 2018-05-30 Gilead Sciences Inc Therapeutic compositions for treatment of human immunodeficiency virus

Also Published As

Publication number Publication date
BR112015014714A2 (pt) 2016-01-05
KR102351912B1 (ko) 2022-01-17
NZ709260A (en) 2016-07-29
CL2016000837A1 (es) 2016-10-21
SI3608325T1 (sl) 2022-09-30
IL239316A (en) 2016-09-29
PH12019501848A1 (en) 2020-03-02
HRP20160544T1 (hr) 2016-07-15
CN107674086B (zh) 2020-03-31
CA3012242A1 (en) 2014-06-26
NO2018026I1 (no) 2018-08-23
US20190092787A1 (en) 2019-03-28
HUE046559T2 (hu) 2020-03-30
MD20200093A2 (ro) 2021-05-31
CY2018022I1 (el) 2019-07-10
HK1250711A1 (zh) 2019-01-11
PT2822954E (pt) 2016-06-16
LT3067358T (lt) 2019-11-25
KR20150096504A (ko) 2015-08-24
TWI752457B (zh) 2022-01-11
UA114351C2 (uk) 2017-05-25
EP2822954A1 (en) 2015-01-14
HRP20191957T1 (hr) 2020-02-07
JP2019023204A (ja) 2019-02-14
IL247311A0 (en) 2016-09-29
US20170057976A1 (en) 2017-03-02
PT3067358T (pt) 2019-11-18
KR102406288B1 (ko) 2022-06-13
ES2753548T3 (es) 2020-04-13
IL274988A (en) 2020-07-30
US10689399B2 (en) 2020-06-23
EP3608325B1 (en) 2022-07-06
UY35213A (es) 2014-06-30
IL239316A0 (en) 2015-07-30
KR20220080208A (ko) 2022-06-14
MY191741A (en) 2022-07-13
DK3608325T3 (da) 2022-08-22
HRP20220899T1 (hr) 2022-10-28
KR20200067930A (ko) 2020-06-12
NZ718708A (en) 2018-11-30
ZA201507997B (en) 2019-09-25
KR20210049956A (ko) 2021-05-06
CN111303152B (zh) 2023-04-11
SMT201600157B (it) 2016-08-31
US20160176885A1 (en) 2016-06-23
JP6933690B2 (ja) 2021-09-08
NL300947I2 (nl) 2018-09-26
PH12016500389A1 (en) 2018-10-01
PH12015501445B1 (en) 2015-09-14
PE20170528A1 (es) 2017-05-28
WO2014100323A1 (en) 2014-06-26
TWI815245B (zh) 2023-09-11
MD4841B1 (ro) 2023-01-31
LUC00083I2 (en) 2018-10-15
PH12015501445A1 (en) 2015-09-14
CA2893843C (en) 2018-09-04
BR122015029881B1 (pt) 2022-04-26
JP2023134483A (ja) 2023-09-27
HUE028284T2 (en) 2016-12-28
US10035809B2 (en) 2018-07-31
ES2926068T3 (es) 2022-10-21
IL245780B (en) 2019-02-28
KR20230061576A (ko) 2023-05-08
KR20190124814A (ko) 2019-11-05
CN116640140A (zh) 2023-08-25
CN104995198A (zh) 2015-10-21
AU2018232957B2 (en) 2020-01-30
AR094197A1 (es) 2015-07-15
JP7301918B2 (ja) 2023-07-03
JP2019218368A (ja) 2019-12-26
TW201441224A (zh) 2014-11-01
AU2013361401C1 (en) 2018-08-09
HK1205124A1 (en) 2015-12-11
AU2021221427B2 (en) 2023-10-12
LTC2822954I2 (lt) 2019-10-10
CA2893843A1 (en) 2014-06-26
TW202212342A (zh) 2022-04-01
MD4736C1 (ro) 2021-07-31
AU2018232957A1 (en) 2018-10-11
TW201918485A (zh) 2019-05-16
EA030003B1 (ru) 2018-06-29
EA201591027A1 (ru) 2016-05-31
PL3608325T3 (pl) 2022-11-07
AP2015008510A0 (en) 2015-06-30
HUS1800035I1 (hu) 2018-09-28
US9216996B2 (en) 2015-12-22
MX344879B (es) 2017-01-11
SG11201504857SA (en) 2015-07-30
EP4122935A1 (en) 2023-01-25
PL3067358T3 (pl) 2020-02-28
CA3131094A1 (en) 2014-06-26
JP2016508134A (ja) 2016-03-17
ES2577283T3 (es) 2016-07-14
AU2016262722B2 (en) 2018-10-18
AU2020202914A1 (en) 2020-05-21
CY2018022I2 (el) 2019-07-10
PE20151499A1 (es) 2015-10-29
CA3012242C (en) 2021-11-02
LT3608325T (lt) 2022-09-12
PT3608325T (pt) 2022-10-17
SI2822954T1 (sl) 2016-07-29
DK2822954T3 (da) 2016-05-30
JP6028105B2 (ja) 2016-11-16
BR112015014714B1 (pt) 2018-12-26
AU2021221427A1 (en) 2021-09-16
MD4754C1 (ro) 2021-12-31
JP6571256B2 (ja) 2019-09-04
CN111303152A (zh) 2020-06-19
MD4736B1 (ro) 2020-12-31
MD4754B1 (ro) 2021-05-31
HK1216643A1 (zh) 2016-11-25
MD20150064A2 (ro) 2015-11-30
AU2013361401A1 (en) 2015-08-27
EA037633B1 (ru) 2021-04-23
SI3067358T1 (sl) 2019-12-31
CY1122246T1 (el) 2020-11-25
AU2016262722A1 (en) 2016-12-08
KR102527797B1 (ko) 2023-05-03
EP3067358A1 (en) 2016-09-14
CR20170279A (es) 2017-10-19
PL2822954T3 (pl) 2016-09-30
CR20150380A (es) 2015-08-21
EP3067358B1 (en) 2019-08-07
CN107674086A (zh) 2018-02-09
US20210053988A1 (en) 2021-02-25
PH12016500389B1 (en) 2018-10-01
EP3608325A1 (en) 2020-02-12
MX2020003055A (es) 2020-07-27
US9732092B2 (en) 2017-08-15
MX357940B (es) 2018-07-31
US20140221356A1 (en) 2014-08-07
AU2013361401B2 (en) 2017-01-05
AU2023286038A1 (en) 2024-01-25
ZA201903516B (en) 2020-01-29
MY164352A (en) 2017-12-15
EP2822954B1 (en) 2016-03-09
HUE059688T2 (hu) 2022-12-28
TWI642669B (zh) 2018-12-01
KR102040007B1 (ko) 2019-11-05
TW202400591A (zh) 2024-01-01
KR20170073733A (ko) 2017-06-28
US9663528B2 (en) 2017-05-30
MX2015008009A (es) 2015-10-22
US11548901B2 (en) 2023-01-10
KR102246963B1 (ko) 2021-04-30
TW202104229A (zh) 2021-02-01
IL245780A0 (en) 2016-08-02
LTPA2018511I1 (lt) 2018-10-10
KR102120875B1 (ko) 2020-06-09
CL2017001191A1 (es) 2018-02-09
JP6411409B2 (ja) 2018-10-24
CN104995198B (zh) 2018-01-30
JP2016179996A (ja) 2016-10-13
KR101770048B1 (ko) 2017-08-21
US20170260204A1 (en) 2017-09-14
AU2020202914B2 (en) 2021-09-09
TWI830624B (zh) 2024-01-21
RS54873B1 (sr) 2016-10-31
UA123572C2 (uk) 2021-04-28
JP2021193090A (ja) 2021-12-23
NO2018026I2 (no) 2018-08-23
KR20220011789A (ko) 2022-01-28
ME02400B (me) 2016-09-20
CL2015001756A1 (es) 2015-08-07
TWI693224B (zh) 2020-05-11
BR122015029881A2 (pt) 2016-03-22
MX2022013596A (es) 2022-11-16
EA201890236A1 (ru) 2018-10-31
CY1117570T1 (el) 2017-04-26

Similar Documents

Publication Publication Date Title
LTPA2018511I1 (lt) Policikliniai karbamoilpiridino junginiai ir jų farmacinis panaudojimas
DK2906684T3 (da) T-celle-modificerende forbindelser og anvendelser deraf
DK2920167T3 (da) Hydrazinyl-indol-forbindelser og konjugater
DK2903600T3 (da) Virusholdig formulering og anvendelse deraf
DK3444281T3 (da) Forbedrede peptidlægemidler
DK2917181T3 (da) Heteroarylderivater og anvendelser deraf
DK2897594T3 (da) Farmaceutisk sammensætning
DK3392252T3 (da) Pyrimido-pyridazinonforbindelser og deres anvendelse
DK2745849T3 (da) Polydeoxyribonukleotidsammensætning og anvendelser deraf
DK2943460T3 (da) 6-chlor-3-(phenyl-d5)-inden-1-on og anvendelse deraf
BR112015002646A2 (pt) composto e composição farmacêutica
DK2964623T3 (da) Substituerede chroman-6-yloxycycloalkaner og deres anvendelse som farmaceutik
BR302012003979S1 (pt) Configuração aplicada em fármaco
BR112014021433A2 (pt) formulações farmacêuticas
FR2988758B1 (fr) Columbarium
ECSP12011630A (es) Formulación farmacéutica